NASDAQ Framework: Intra-Cellular Therapies Inc.

Biopharmaceutical company focused on CNS disorders 123.
1: With the business potentially at an important milestone, we thought we'd take a closer look at Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) future prospects. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The US$7.9b market-cap company posted a loss in its most recent financial year of US$140m and a latest trailing-twelve-month loss of US$111m shrinking the gap between loss and breakeven. The most pressing concern for investors is Intra-Cellular Therapies' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. View Source2: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. View Source3: Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. View Source
Intra-Cellular Therapies Inc. is a biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States 456. Founded on Nobel prize-winning research, the company leverages its proprietary chemistry platforms to develop innovative treatments for complex psychiatric and neurologic diseases 78. Intra-Cellular Therapies offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults and is actively developing other therapeutic candidates, including Lumateperone, Lenrispodun (ITI-214), ITI-1284, and ITI-333, for various neuropsychiatric and neurological conditions 9.
4: With the business potentially at an important milestone, we thought we'd take a closer look at Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) future prospects. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The US$7.9b market-cap company posted a loss in its most recent financial year of US$140m and a latest trailing-twelve-month loss of US$111m shrinking the gap between loss and breakeven. The most pressing concern for investors is Intra-Cellular Therapies' path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. View Source5: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders. View Source6: Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. View Source7: Intra-Cellular Therapies, Inc. is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to deliver innovative treatments for people living with complex psychiatric and neurologic diseases. WORK WITH US Patient needs are at the core of our efforts at Intra-Cellular Therapies and we are always looking for talented individuals who share our values to join our team. Please explore open positions by clicking the “Jobs” tab above. View Source8: About Intra-Cellular TherapiesIntra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com. View Source9: Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. View Source
UNKNOWN

The provided facts do not specify whether Intra-Cellular Therapies Inc. is still led by its founders or if the founders are heavily involved in the company [f39013-f38993]UNKNOWN

The provided facts do not specify whether Intra-Cellular Therapies Inc. is still led by its founders or if the founders are heavily involved in the company [f39013-f38993].
MEDIUM RISK

Intra-Cellular Therapies Inc. is currently not profitable, with a net margin of -10.53% and a return on equity (ROE) of -2.56% 1011. However, the company has no debt on its balance sheet, which reduces financial risk 12. Analysts expect the company to break even by 2025, indicating a high growth rate of 60% year-on-year 13. While the company has shown solid revenue growth of 52.9% in recent months 14, the lack of profitability and reliance on future growth projections place it in the medium risk category.
10: Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.53%, the company may face hurdles in effective cost management. View Source11: Return on Equity (ROE): Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.56%, the company may face hurdles in achieving optimal financial performance. View Source12: Before we wrap up, there’s one aspect worth mentioning. Intra-Cellular Therapies currently has no debt on its balance sheet, which is rare for a loss-making pharma, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company. View Source13: Intra-Cellular Therapies is bordering on breakeven, according to the 15 American Pharmaceuticals analysts. They expect the company to post a final loss in 2024, before turning a profit of US$114m in 2025. So, the company is predicted to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2025? Working backwards from analyst estimates, it turns out that they expect the company to grow 60% year-on-year, on average, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. View Source14: Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 52.9%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers. View Source
YES

Intra-Cellular Therapies Inc. is actively developing new therapeutic candidates, including Lumateperone, Lenrispodun (ITI-214), ITI-1284, and ITI-333, for various neuropsychiatric and neurological conditions 15.
15: Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. View Source
Intra-Cellular Therapies Inc. is poised for significant growth from 2024 through 2026, focusing on the development and commercialization of several promising therapeutic candidates. The company's product roadmap includes advancing Lumateperone, currently in Phase 3 clinical trials for various depressive disorders, and Lenrispodun (ITI-214) for Parkinson's disease and other CNS disorders. Additionally, ITI-1284 is being developed for neuropsychiatric disorders and behavioral disturbances in dementia, while ITI-333 targets substance use disorders, pain, and psychiatric comorbidities. Analysts project that Intra-Cellular Therapies will achieve profitability by 2025, driven by an aggressive annual growth rate of 60% [fERROR]Intra-Cellular Therapies Inc. is poised for significant growth from 2024 through 2026, focusing on the development and commercialization of several promising therapeutic candidates. The company's product roadmap includes advancing Lumateperone, currently in Phase 3 clinical trials for various depressive disorders, and Lenrispodun (ITI-214) for Parkinson's disease and other CNS disorders. Additionally, ITI-1284 is being developed for neuropsychiatric disorders and behavioral disturbances in dementia, while ITI-333 targets substance use disorders, pain, and psychiatric comorbidities. Analysts project that Intra-Cellular Therapies will achieve profitability by 2025, driven by an aggressive annual growth rate of 60% [fERROR][fERROR]Intra-Cellular Therapies Inc. is poised for significant growth from 2024 through 2026, focusing on the development and commercialization of several promising therapeutic candidates. The company's product roadmap includes advancing Lumateperone, currently in Phase 3 clinical trials for various depressive disorders, and Lenrispodun (ITI-214) for Parkinson's disease and other CNS disorders. Additionally, ITI-1284 is being developed for neuropsychiatric disorders and behavioral disturbances in dementia, while ITI-333 targets substance use disorders, pain, and psychiatric comorbidities. Analysts project that Intra-Cellular Therapies will achieve profitability by 2025, driven by an aggressive annual growth rate of 60% [fERROR][fERROR].